**Sir,**

We read with great interest the article 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer\' published by ([@bib11]) in the December 2013 issue of the *British Journal of Cancer*. It is now well established that only patients with wild-type *KRAS* metastatic colorectal cancer benefit from treatment with an anti-epidermal growth factor receptor (EGFR) monoclonal antibody and that patients with *KRAS* mutant metastatic colorectal cancer do not ([@bib5]; [@bib3]). Up until now, DNA from archival tumour tissue is used to determine *KRAS* mutations in clinical practice. Increased recent data indicate that circulating tumour DNA in plasma, could be a new way to analyse the somatic mutation in tumours and could be a potential biomarker to ensure optimal treatment ([@bib8]). Spindler *et al* (2013) aimed to investigate the clinical implication of *KRAS* and *BRAF* mutations in both archival tumour tissue and plasma cell-free DNA in 211 metastatic colorectal cancer patients treated with second-line irinotecan monotherapy. Authors observed that plasma *KRAS* mutations, but not tumour *KRAS* mutations, were associated with worse disease control rate, progression-free survival and overall survival. However, contrary to what is mentioned in the title, the predictive impact of the plasma *KRAS* and *BRAF* mutations for the irinotecan response treatment cannot be evaluated in this study because there is no control arm (patients receiving other therapies or no therapy).

In this study, *KRAS* mutations have been detected less frequently in plasma (31%) as compared in tumour (45%) (16 patients with a wild-type *KRAS* plasma had a mutation in the tumour). Tumour *KRAS* mutations were analysed in formalin-fixed paraffin-embedded tissue obtained at diagnosis, whereas plasma *KRAS* mutations were analysed in pretreatment blood samples before the beginning of second-line irinotecan monotherapy. The description of patients receiving an anti-EGFR in first-line therapy would be an interesting information, as acquired *KRAS* mutations can be induced by these therapies ([@bib7]). The presence of a minority subclone harbouring *KRAS* mutations within tumours might explain the secondary resistance to anti-EGFR therapy ([@bib15]) and the emergence of plasma *KRAS* mutations ([@bib1]).

Furthermore, the discordance for the *KRAS* mutation detection rate between tumour and plasma could be explained by a lack of sensitivity for the plasma *KRAS* mutations detection or by the absence of circulating tumour DNA for some patients. The amplification refractory mutation system-quantitative PCR (ARMS-qPCR) methodology, used in this study, has a sensitivity around 0.1% ([@bib4]; [@bib9]). Some studies have suggested that ARMS has an insufficient sensitivity to detect low levels of *KRAS* mutation ([@bib9]). Indeed, the level of circulating tumour DNA in plasma can be very low and may represent only a small fraction of the total circulating DNA (\<0.01%) ([@bib2]; [@bib14]). Techniques with very high sensitivity for circulating tumour DNA detection have been recently developed ([@bib13]), such as microdroplet technology, which can detect one mutant *KRAS* gene among 200 000 wild-type *KRAS* genes in the plasma ([@bib10]). Thus, we think that the results of the study by [@bib11] should be interpreted with caution because the poor prognosis of patients with plasma *KRAS* mutation could only reflect the poor prognosis of patients with a high level of circulating tumour DNA, as suggested by some others studies ([@bib6]; [@bib12]). In contrast, the better prognosis could only reflect the low level of circulating tumour DNA that is not detectable by the ARMS assay for the *KRAS* mutation testing.

In conclusion, this promising work published by [@bib11]) highlights the impact of circulating tumour DNA on the treatment response of metastatic colorectal cancer. Moreover, it strengthens the need for harmonising detection methods for *KRAS* mutations and to develop highly sensitive techniques for plasma testing. Thus, correlation of *KRAS* mutation in primary tumours, metastases and plasma during metastatic colorectal therapies still needs to be studied.
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